No matches
Dermatology

Exploring the Potential Role of Biomarkers in Managing Bullous Pemphigoid

Dr. Donna Culton discusses biomarkers in bullous pemphigoid and considers their potential clinical use.
Donna Aline Culton
MD, PhD
Donna Aline Culton

Related resources

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

interactivity
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

expert video
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

expert video
Atopic Dermatitis in Children: Not Just a Skin Disease

Atopic Dermatitis in Children: Not Just a Skin Disease

expert video
Type 2 Inflammation and Its Role in Atopic Dermatitis

Type 2 Inflammation and Its Role in Atopic Dermatitis

expert video
Persistence of AD From Childhood Into Adulthood

Persistence of AD From Childhood Into Adulthood

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
Early Intervention and the Potential For Disease Modification in AD

Early Intervention and the Potential For Disease Modification in AD

expert video
Emerging Real-World Data on Advanced Systemic Therapies in AD

Emerging Real-World Data on Advanced Systemic Therapies in AD

expert video
Real-World Effectiveness of Advanced Systemic Treatments in AD

Real-World Effectiveness of Advanced Systemic Treatments in AD

expert video
The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

expert video
Unmet Needs in Bullous Pemphigoid

Unmet Needs in Bullous Pemphigoid

expert video
Diagnosis and Clinical Manifestations of Bullous Pemphigoid

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

expert video
Pathophysiology of Bullous Pemphigoid

Pathophysiology of Bullous Pemphigoid

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid

Bullous Pemphigoid (BP) Pathophysiology Infographic

Infographic
CSU Burden Related to Chronicity and Patient Journey

CSU Burden Related to Chronicity and Patient Journey

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

expert video
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

expert video
The Importance of Disease Control in Reducing CSU Patient Burden

The Importance of Disease Control in Reducing CSU Patient Burden

expert video
Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

expert video

Learning objectives

  • Learn what biomarkers are relevant in bullous pemphigoid
Tags
type 2 inflammationIL-4IL-13histologybiomarkersBullous Pemphigoid
MAT-GLB-2602219 -1.0 -06/2026

About this expert

Dermatology

Donna Aline Culton

MD, PhD

Professor of Dermatology Associate Director, Clinical Trials Unit Director, Clinical Immunofluorescence Laboratory  University of North Carolina, Chapel Hill Chapel Hill, NC, USA

See author’s profile
Donna Aline Culton

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region